NCT02825979 - Early Aggressive Invasive Intervention for Atrial Fibrillation | Biotech Hunter

Enrollment

303

Participants

Timeline

Start Date

January 31, 2017

Primary Completion Date

September 30, 2022

Study Completion Date

November 30, 2022

Conditions

Atrial Fibrillation

Interventions

PROCEDURE

Cryoballoon-based PVI

Patients randomized to first-line cryoballoon (CB) ablation will have the pulmonary vein isolation procedure performed according to standard clinical practice using the Arctic Front Cryoballoon ablation catheter. No anti-arrhythmic drugs will be prescribed in this arm.

DRUG

Anti-Arrhythmic Drug Therapy

Antiarrhythmic drug therapy (Class I - flecainide, propafenone; Class III - sotalol, dronedarone) will prescribed and monitored based on local clinical practice, and according to guideline-suggested drug management for symptomatic patients with paroxysmal AF.

Trial Locations (18)

Unknown

Libin CV Calgary, Calgary

Royal Alexandra, Edmonton

St. Paul's Hospital, Vancouver

Vancouver General Hospital, Vancouver

Queen Elizabeth II, Halifax

London Health Sciences Centre, London

Southlake Regional Health Centre, Newmarket

Rouge Valley Health System, Scarborough Village

St. Michael's Hospital, Toronto

McGill University Health Centre, Montreal

Institut Universitaire de Cardiologie et de Pneumologie de Quebec, Québec

Le Centre hospitalier universitaire de Sherbrooke CHUS, Sherbrooke

University of Saskatchewan, Saskatoon

V8T 1Z4

Victoria Cardiac Arrhythmia Trials, Victoria

L8L 2X2

Hamilton Health Sciences, Hamilton

N2M 1B2

St. Mary's Kitchener, Kitchener

K1Y4W7

University of Ottawa Heart Institute, Ottawa

H4J 1C5

Hôpital du Sacré-Cœur de Montréal, Montreal